Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sedation with remimazolam vs midazolam plus dexmedetomidine during gastric and colorectal ESD
jRCTs051260056Not yet recruiting
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial in gastric cancer (GC) and colorectal cancer (CRC) comparing Remimazolam arm with Midazolam plus dexmedetomidine arm (2 arms). Primary endpoint: Post-procedural level of consciousness. Planned start May 2026; status: not yet recruiting.
02
Drugs
remimazolammidazolamdexmedetomidine
03
Conditions
gastric cancer (GC)colorectal cancer (CRC)
Beyond the preview
Go deeper on jRCTs051260056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051260056.